Cefoperazone-sulbactam in the treatment of the hospital-acquired pneumonia caused by pandrug-resistant Acinetobacter baumannii:a report of 36 cases

Objective To evaluate the clinical effect of large dose of cefoperazone-sulbactam on hospital-acquired pneumonia(HAP) caused by carbapenem-resistant Acinetobacter baumannii,so as to support the reasonable use of antibacterial agents.MethodsA total of 36 patients in the ICU were confirmed as HAP caused by carbapenem-resistant Acinetobacter baumannii by way of sputum culture and susceptibility testing from June 2010 to December 2011.These patients were treated with cefoperazone-sulbactam 3.0 g or 2.25 g(if renal insufficiency),IV infusion,every 6 hours,for at least 7 days.The clinical efficacy,bacteriological efficacy and adverse reactions were well recorded and analyzed retrospectively.ResultsThe HAP was cured in 20 patients,improved in 10 patients,ineffective in 6 patients after treatment with cefoperazone-sulbactam.The overall efficacy rate was 55.5%.The bacterial pathogen was cleared in 15 of the 36 patients(41.6%).The mean duration of treatment was 14.3 ± 5.6 days.Adverse reactions were observed in only 4 patients(11.1%).ConclusionsHigh dose cefoperazone-sulbactam has showed good therapeutic effect on the HAP caused by carbapenem-resistant Acinetobacter baumannii with few adverse reactions.It may be one of the best choices for the HAP caused by pandrug resistant A.baumannii in ICU.